426828-34-4

Basic information

• Product Name: 4-Amidinotetrahydro-2H-pyran hydrochloride
• Synonyms: 4-Amidinotetrahydro-2H-pyran hydrochloride;Tetrahydro-2H-pyran-4-carboxamidine hydrochloride;tetrahydropyran-4-carboxamidine hydrochloride;Tetrahydro-2H-pyran-4-carboxamidine hydrochloride 97%;Tetrahydropyran-4-carboxaMidine HCl;oxane-4-carboxiMidaMide hydrochloride;Tetrahydropyran-4-carboxa...;Tetrahydro-2H-pyran-4-carboximidamide hydrochloride
• CAS NO: 426828-34-4
• Molecular Formula: C₆H₁₂N₂O*ClH
• Molecular Weight: 0
• Mol File: 426828-34-4.mol

Chemical Properties

• Boiling Point: 223.2°C at 760 mmHg
• Flash Point: 88.8°C
• Appearance: /
• Vapor Pressure: 0.0972mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-Amidinotetrahydro-2H-pyran hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amidinotetrahydro-2H-pyran hydrochloride(426828-34-4)
• EPA Substance Registry System: 4-Amidinotetrahydro-2H-pyran hydrochloride(426828-34-4)

Safety Data

• Hazardous Substances Data: 426828-34-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Development:
4-Amidinotetrahydro-2H-pyran hydrochloride is used as a therapeutic agent for the treatment of thrombotic disorders, leveraging its ability to inhibit PAI-1 and thus promote fibrinolysis to prevent blood clot formation.
Used in Laboratory Research:
4-Amidinotetrahydro-2H-pyran hydrochloride serves as a valuable research tool for studying the role of PAI-1 in various physiological and pathological processes, contributing to a deeper understanding of the fibrinolytic system and its implications in health and disease.
Used in Drug Delivery Systems:
While not explicitly mentioned in the provided materials, given the compound's potential therapeutic applications, it is plausible that 4-Amidinotetrahydro-2H-pyran hydrochloride could be incorporated into drug delivery systems to enhance its bioavailability, targeting, and overall efficacy in treating thrombotic conditions. This would involve the development of formulations that optimize the compound's release and interaction with biological targets while minimizing side effects.

InChI:InChI=1/C6H12N2O.ClH/c7-6(8)5-1-3-9-4-2-5;/h5H,1-4H2,(H3,7,8);1H

Upstream product

• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 
• 4295-99-2 tetrahydro-2H-pyran-4-carbonitrile 
• 908291-42-9 methyl tetrahydropyran-4-imidate hydrochloride 

Relevant articles and documents

[tetorahidoropiranirupirimijin[tetorahidoropiranirupirimijin] compound

PROBLEM TO BE SOLVED: To provide an industrially preferable production method for obtaining a tetrahydropyranyl pyrimidine compound in high yield without performing complicated operations.SOLUTION: There is provided a method of producing a tetrahydropyranyl pyrimidine compound of the general formula (4), including reacting a tetrahydropyran-4-carboxy amidine compound of the chemical formula (1) (or acid salt thereof) and a compound represented by the general formula (2) in the presence of a base. In the formulae, one of Rand Rrepresents an alkoxy group or -NRRand the other represents a hydrogen atom or an alkoxy group, Arepresents an alkoxycarbonyl group, a cyano group, a formyl group or an iminium group, Z represents a hydrogen atom, an amino group, a hydroxyl group or a halogen atom.

PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE

Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, auutoimmune and cardiovascular diseases.

5-ETHYL-IMIDAZO (5,1-F) (1,2,4,) TRIAZIN-4 (3H) -ONES AS PHOSPHODIESTERASE INHIBITORS

The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

A novel approach to amidines from esters

A mild and efficient method for the direct conversion of aromatic, benzylic and aliphatic esters to amidines - in the form of their hydrochlorides - has been developed.